Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2b|
|Storage buffer||PBS with 4mg/ml BSA|
|Contains||0.1% sodium azide|
|Storage Conditions||4° C, store in dark|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay-Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Commonly used, FITC conjugates provide relatively high absorptivity, excellent fluorescence quantum yield, and good water solubility.
HLA-DRA is one of the HLA class II alpha chain paralogues. This class II molecule is a heterodimer consisting of an alpha and a beta chain, both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The alpha chain is approximately 33-35 kDa and its gene contains 5 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, and exon 4 encodes the transmembrane domain and the cytoplasmic tail. DRA does not have polymorphisms in the peptide binding part and acts as the sole alpha chain for DRB1, DRB3, DRB4 and DRB5.
Analyte Specific Reagent
Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin.
MHLDR01 was used in flow cytometry to study the role of melanoma cell surface-associated calreticulin in melphalan-induced antitumor immunity.
|Dudek-Peri¿ AM,Ferreira GB,Muchowicz A,Wouters J,Prada N,Martin S,Kiviluoto S,Winiarska M,Boon L,Mathieu C,van den Oord J,Stas M,Gougeon ML,Golab J,Garg AD,Agostinis P||Cancer research (75:1603)||2015|
Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells.
MHLDR01 was used in flow cytometry to study the role of autophagy in melanoma
|Martin S,Dudek-Peri¿ AM,Maes H,Garg AD,Gabrysiak M,Demirsoy S,Swinnen JV,Agostinis P||Biochemical pharmacology (93:290)||2015|
Susceptibility of human placenta derived mesenchymal stromal/stem cells to human herpesviruses infection.
MHLDR01 was used in flow cytometry to assess the susceptibility of fetal membranes-derived mesenchymal stromal/stem cells to all members of the human Herpesviridae family.
|Avanzi S,Leoni V,Rotola A,Alviano F,Solimando L,Lanzoni G,Bonsi L,Di Luca D,Marchionni C,Alvisi G,Ripalti A||PloS one (8:null)||2013|
Abnormal cell surface antigen expression in individuals with variant CD45 splicing and histiocytosis.
MHLDR01 was used in flow cytometry to study CD45 splice variants in patients with hemophagocytic lymphohistiocytosis.
|Boxall S,McCormick J,Beverley P,Strobel S,De Filippi P,Dawes R,Klersy C,Clementi R,De Juli E,Ferster A,Wallace D,Aricò M,Danesino C,Tchilian E||Pediatric research (55:478)||2004|
Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus.
MHLDR01 was used in flow cytometry to report that CD34(+) progenitor cell-derived Langerhans cells-type DCs exhibit a differentiation state-dependent susceptibility to CMV infection.
|Hertel L,Lacaille VG,Strobl H,Mellins ED,Mocarski ES||Journal of virology (77:7563)||2003|
Expression of CD41 and c-mpl does not indicate commitment to the megakaryocyte lineage during haemopoietic development.
MHLDR01 was used in flow cytometry to report that the expression of CD41 and c-mpl were not predictive of commitment to the megakaryocyte lineage.
|Basch RS,Zhang XM,Dolzhanskiy A,Karpatkin S||British journal of haematology (105:1044)||1999|
Clone P2-beta-3; DR alpha chain; DR-16; DW2.2/DR2.2; histocompatibility antigen HLA-DR alpha; HLA class II histocompatibility antigen; HLA class II histocompatibility antigen, DR-1 beta chain; HLA class II histocompatibility antigen, DRB1-15 beta chain; HLA class II histocompatibility antigen, DRB1-16 beta chain; HLA class II histocompatibility antigen, DRB1-3 chain; HLA-DRA1; human leucocyte antigen DRB1; lymphocyte antigen DRB1; MHC cell surface glycoprotein; MHC class II antigen; MHC class II antigen DRB1*15; MHC class II antigen DRB1*16; MHC class II antigen DRB1*3; MHC class II HLA-DR beta 1 chain; MHC class II HLA-DR-beta cell surface glycoprotein; MHC class II HLA-DRw10-beta; MLRW
DRB1; DRw10; HLA-DR1B; HLA-DRB; HLA-DRB1; HLA-DRB2; SS1